Clinical trial NCT00079430: Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Official title: A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Brenner Tumor
Fallopian Tube Cancer
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mixed Epithelial Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Primary Peritoneal Cavity Cancer
Stage II Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
Collaborators: name: Gynecologic Oncology Group
First posted: 2004-03-10
Enrollment: 113
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase I trial is studying the side effects and best dose of adjuvant intraperitoneal carboplatin when given together with paclitaxel and bevacizumab in treating patients who have undergone debulking surgery for stage II , stage III, or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin and paclitaxel in treating ovarian epithelial or primary peritoneal cancer, or fallopian tube cancer.

Detailed description: PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of intraperitoneal carboplatin when administered with paclitaxel during course 1, in patients with stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer who had initial debulking surgery.

II. Determine the feasibility of this regimen in these patients. III. Determine the feasibility of adding IV bevacizumab to this regimen in courses 2-6.

SECONDARY OBJECTIVES:

I. Determine the toxicity profile of this regimen in these patients. II. Determine the toxicity profile of paclitaxel and bevacizumab IV in combination with intraperitoneal carboplatin in these patients.

III. Determine the response rate (in patients with measurable disease who are in the expanded cohort) and progression-free survival of patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of intraperitoneal carboplatin.

Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of carboplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 20-40 patients are treated at that dose level.

Patients are followed every 3 months for 1 year.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

  * Stage II-IV disease
* The following histologic epithelial cell types are eligible:

  * Serous adenocarcinoma
  * Mucinous adenocarcinoma
  * Clear cell adenocarcinoma
  * Transitional cell carcinoma
  * Adenocarcinoma not otherwise specified
  * Endometrioid adenocarcinoma
  * Undifferentiated carcinoma
  * Mixed epithelial carcinoma
  * Malignant Brenner's tumor
* Optimal (≤ 1 cm residual disease) OR suboptimal residual disease after initial debulking surgery (performed within the past 12 weeks)
* Synchronous primary endometrial cancer OR prior history of endometrial cancer allowed provided all of the following are true:

  * Stage IB disease or less
  * Less than 3 mm invasion without vascular or lymphatic invasion
  * No poorly differentiated subtypes, including the following:

    * Papillary serous
    * Clear cell
    * Other FIGO grade 3 lesions
* No epithelial tumors of low malignant potential (borderline tumors)
* No CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, or brain metastases by history or evidence upon physical examination within the past 6 months
* Performance status - GOG 0-2
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* INR ≤ 1.5
* PTT \< 1.2 times upper limit of normal (ULN)
* No active bleeding or pathologic conditions carrying high risk of bleeding (e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels)
* AST ≤ 3 times upper limit of normal (ULN)
* Alkaline phosphatase ≤ 3 times ULN
* Bilirubin ≤ 1.5 times ULN
* No acute hepatitis
* Creatinine ≤ 2.0 mg/dL
* Urine protein-creatinine ratio \< 1.0 OR protein 1.0 g by 24 hour urine collection
* Cardiac conduction abnormalities (e.g., bundle branch block or heart block) allowed provided the patient's cardiac status has been stable for ≥ 6 months before study entry
* No clinically significant cardiovascular disease, including any of the following:

  * Uncontrolled hypertension, defined as systolic BP \> 150 mm Hg or diastolic BP \> 90 mm Hg
  * Myocardial infarction or unstable angina within the past 6 months
  * New York Heart Association class II-IV congestive heart failure
  * Serious cardiac arrhythmia requiring medication
  * Peripheral vascular disease ≥ CTCAE grade 2 (at least brief (\< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit)
  * No history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within the past 6 months
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for ≥ 6 months after completion of bevacizumab therapy
* No neuropathy (sensory and motor) \> grade 1
* No active infection requiring antibiotics
* No circumstances that would preclude study participation
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
* No history of allergic reaction to polysorbate 80 (e.g., etoposide, vitamin E)
* No other invasive malignancies within the past 5 years except non-melanoma skin cancer or localized breast cancer
* No serious, non-healing wound, ulcer, or bone fracture
* No significant traumatic injury within 28 days prior to bevacizumab therapy
* No prior history of abdominal fistula or gastrointestinal perforation within the past 3-6 months

  * Granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection allowed but require weekly wound examinations
* No clinical symptoms or signs of gastrointestinal obstruction requiring parenteral hydration and/or nutrition
* At least 28 days since intra-abdominal abscess and recovered
* At least 3 years since prior adjuvant chemotherapy for localized breast cancer

  * Patients must remain free of recurrent or metastatic disease
* At least 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin

  * Patient must remain free of recurrent or metastatic disease
* No prior radiotherapy to any portion of the abdominal cavity or pelvis
* No concurrent amifostine or other protective agents
* No concurrent major surgical procedure or open biopsy or within 28 days prior to bevacizumab therapy
* No core biopsy within 7 days prior to bevacizumab therapy
* No prior therapy for this malignancy
* No prior cancer treatment that contraindicates study therapy
* No prior anti-VEGF drug, including bevacizumab

Primary outcomes:
measure: Maximum tolerated dose (MTD) of intraperitoneal carboplatin with intravenous paclitaxel, determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)
timeFrame: 3 weeks
measure: Incidence of adverse events in patients given intraperitoneal carboplatin with intravenous paclitaxel at the MTD, assessed by CTCAE v3.0
timeFrame: 12 weeks
measure: Number of observed DLTs in patients given intraperitoneal carboplatin with intravenous paclitaxel and intravenous bevacizumab, graded using CTCAE v3.0
timeFrame: 6 weeks
Secondary outcomes:
measure: Incidence of adverse events in patients given intraperitoneal carboplatin with intravenous paclitaxel and intravenous bevacizumab, graded using CTCAE v3.0
timeFrame: 12 weeks
measure: Response rate (in patients with measurable disease who are in the expanded cohort) assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
timeFrame: Up to 1 year
measure: Progression-free survival assessed by RECIST
timeFrame: From study entry until disease progression, death or date of last contact, up to 1 year
Other outcomes:
Locations:
city: Orange
country: United States
facility: University of California Medical Center At Irvine-Orange Campus
state: California
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Iowa City
country: United States
facility: University of Iowa Hospitals and Clinics
state: Iowa
city: Baltimore
country: United States
facility: Johns Hopkins University/Sidney Kimmel Cancer Center
state: Maryland
city: Camden
country: United States
facility: Cooper Hospital University Medical Center
state: New Jersey
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
city: Columbus
country: United States
facility: Riverside Methodist Hospital
state: Ohio
city: Tulsa
country: United States
facility: Cancer Care Associates-Midtown
state: Oklahoma
city: Tulsa
country: United States
facility: Tulsa Cancer Institute
state: Oklahoma
city: Philadelphia
country: United States
facility: Gynecologic Oncology Group
state: Pennsylvania
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Providence
country: United States
facility: Women and Infants Hospital
state: Rhode Island
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
city: Seattle
country: United States
facility: Pacific Gynecology Specialists
state: Washington
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
state: Washington
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance
state: Washington
city: Seattle
country: United States
facility: University of Washington Medical Center
state: Washington
city: Okayama-Ken
country: Japan
facility: Kawasaki Medical School
state: Kurashiki
city: Saitama
country: Japan
facility: Saitama Medical University International Medical Center
Study officials:
affiliation: Gynecologic Oncology Group
name: Mark Morgan
role: PRINCIPAL_INVESTIGATOR
References: